Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 8, Issue 10, Pages 783-793Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd2959
Keywords
-
Funding
- National Institutes of Health [P01 AG09215, P30 AG10124, P01 AG11542, P01 AG14382, P01 AG14449, P01 AG17586, PO1 AG19724, P01 NS-044,233, UO1 AG24904]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044233] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [P01AG019724, P01AG011542, P01AG009215, P01AG014382, U19AG010483, P30AG010124, P01AG017586, U01AG024904, P01AG014449] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Neuronal inclusions comprised of the microtubule-associated protein tau are found in numerous neurodegenerative diseases, commonly known as tauopathies. In Alzheimer's disease-the most prevalent tauopathy-misfolded tau is probably a key pathological agent. The recent failure of amyloid-beta-targeted therapeutics in Phase III clinical trials suggests that it is timely and prudent to consider alternative drug discovery strategies for Alzheimer's disease. Here, we focus on strategies directed at reducing misfolded tau and compensating for the loss of normal tau function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available